Beyfortus
Jul 21, 2023
Beyfortus: A New Respiratory Syncytial Virus (RSV) Drug for Toddlers
Sanofi’s immunization strategy is taking shape, owing to an authorization that could drive the company and its partner AstraZeneca to the forefront of the respiratory syncytial virus (RSV) treatment battle. The FDA approved Sanofi and AstraZeneca’s monoclonal antibody Beyfortus, also known as nirsevimab, as a preve...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
